Insmed Inc (INSM)vsUroGen Pharma Ltd (URGN)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
URGN
UroGen Pharma Ltd
$18.12
+2.60%
HEALTHCARE · Cap: $857.78M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 452% more annual revenue ($606.42M vs $109.79M). INSM leads profitability with a -2.1% profit margin vs -139.8%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
URGN
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 54.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -14.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : URGN
The strongest argument for URGN centers on Revenue Growth, Debt/Equity. Revenue growth of 54.0% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : URGN
The primary concerns for URGN are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while URGN is a hypergrowth play — different risk/reward profiles.
URGN carries more volatility with a beta of 1.37 — expect wider price swings.
URGN is growing revenue faster at 54.0% — sustainability is the question.
URGN generates stronger free cash flow (-38M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
UroGen Pharma Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
UroGen Pharma Ltd (URGN) is a biotechnology company focused on pioneering therapies for urological conditions, particularly urothelial carcinoma and bladder cancer. Utilizing its proprietary reverse thermal gel platform, UroGen facilitates sustained local drug delivery, enhancing therapeutic effectiveness while minimizing systemic exposure. The company boasts a robust clinical pipeline aimed at addressing critical unmet needs within urology, positioning itself as a leader in the sector with the potential to significantly improve patient outcomes.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?